PSPothanur Mayavan Sasikala

Pothanur Mayavan Sasikala

*This is an algorithmically generated author record based on publicly available information.

Pothanur Mayavan Sasikala has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ELEVATED CIRCULATING ENDOTHELIN-1 AND OXIDATIVE STRESS AS POTENTIAL BIOMARKERS FOR PREECLAMPSIA IN WOMEN FROM TAMILNADU: A CASE CONTROL STUDY.

    by P. Bagavathiammal, P. M. Sasikala, R. Menaha, Revathi A, Panneerselvam Periasamy, Sasikala Gunasekaran

    Background Preeclampsia (PE) is a hypertensive disorder of pregnancy characterized by endothelial dysfunction and oxidative stress, contributing to maternal and fetal morbidity. Endothelin-1 (ET-1), a potent vasoconstrictor, has been implicated in the pathogenesis of PE. Objective: This study aimed to evaluate ET-1 and oxidative stress markers as potential biomarkers for preeclampsia in pregnant women from Erode, Tamil Nadu. Methods A prospective case-control study was conducted at Government Erode Medical College Hospital, involving 86 pregnant women. Participants were categorized into preeclamptic cases (n = 46) and normotensive controls (n = 40). Serum levels of ET-1, total oxidative status (TOS), total antioxidative status (TAS), and oxidative stress index (OSI) were measured. Independent t-tests and Pearson’s correlation were performed to evaluate group differences and associations. Results The preeclamptic group had significantly elevated ET-1 (1.39 ± 1.31 pg/ml vs. 1.27 ± 0.285 pg/ml, p = 0.023), higher TOS (119.44 ± 6.48 µmol/L vs. 112.88 ± 3.23 µmol/L, p = 0.034), lower TAS (1.04 ± 0.259 mmol/L vs. 1.47 ± 0.388 mmol/L, p = 0.001), and higher OSI (1.44 ± 1.29 vs. 0.867 ± 0.421, p < 0.001). Demographic variables such as mean age (24.01 ± 3.43 vs. 22.64 ± 2.16 years), gravidity, and gestational age (33.1 ± 4 vs. 32 ± 4.3 weeks) showed no significant differences, confirming matched groups. Pearson’s correlation revealed a weak, non-significant association between ET-1 and OSI. Conclusion Preeclampsia is associated with elevated oxidative stress and ET-1 levels, supporting their role as potential biomarkers. These findings may aid in early diagnosis and improved clinical monitoring of PE. Recommendations Future multi-center studies with larger cohorts and longitudinal follow-up are recommended to confirm these findings, explore causal mechanisms, and evaluate the utility of ET-1 and oxidative stress markers for risk stratification and therapeutic interventions in high-risk pregnancies.

  • Open Access

    Comparison of serum copper levels between coronary artery disease patients and normal individuals: a case-control study

    by Zinnia Shivaji Rajan, Sowndharya Jaganathan, Synthiya Arokiasamy, Suganya Kandhi, Pothanur Mayavan Sasikala

    Cardiovascular diseases (CVD) are the leading causes of death in technologically developed and developing countries. Copper, an active redox element, is involved in energy production through various mechanisms. Copper and coronary artery disease can be associated directly, through its direct effect on the vascular endothelium, or indirectly through lipoprotein metabolism. Hence an evaluation of copper in the coronary artery disease individual is important. The aim is to compare the relationship of serum copper levels between coronary artery disease patients and control individuals based on age, sex, hypertension and diabetes mellitus. Materials and methods: The study design was a case-control study in which proven coronary artery disease patients attending cardiology OPD were selected as cases. Control individuals were mainly selected from the master health check-up. Serum copper levels, plasma glucose, cholesterol, serum triglycerides, and serum HDL & LDL cholesterol were done. Glycated haemoglobin (HbA1C) was also measured. The data were analyzed using IBM SPSS software version 24. Result: The correlation of serum copper level with other quantitative parameters is determined by calculating Pearson’s correlation coefficient among cases and controls. Conclusion: The serum copper level is significantly (p=0.001) higher in CAD patients than in age, sex, DM, and HT-matched controls. The serum copper level has a significant (p=0.001) effect on disease, and the adjusted odds ratio is 1.032 (CI 1.011–1.054). In addition, the serum copper level has a significant (0.01) negative correlation with LDL cholesterol and total cholesterol.

  • Open Access

    A cross-sectional study to assess proteinuria and lipoprotein (a) levels in chronic kidney disease

    by Subalakshmi Radhakrishnan, Vijayapriya Indirajith, Periyandi Chandran, Ganesan Subramanyam, Menaha Ramu, Suganya Kandhi, Pothanur Mayavan Sasikala

    Chronic kidney disease (CKD) is a reduced glomerular filtration rate and/or increased urinary albumin excretion. The worldwide prevalence of chronic kidney disease (CKD) ranges from 8 to 16 %, and the prevalence of CKD is rising. The aim: To study the association between CKD stages, proteinuria, and lipoprotein (a) levels among the study participants. Materials and methods: This study was an institution-based observational case-control study involving CKD patients as study group and healthy volunteers as control one. Blood samples were tested for urea, serum creatinine, uric acid levels, triglycerides, total cholesterol, HDL cholesterol, VLDL cholesterol and serum lipoprotein. Statistical analysis was done with SPSS version 20.0. Result: In our study, the most common age group affected among cases was 41 to 50 years (5th decade), and there was a male preponderance in CKD. CKD patients had a higher mean protein creatinine ratio than controls, and this difference was statistically significant. In addition, CKD patients had significantly higher total cholesterol, triglyceride levels and lower HDL cholesterol levels than controls. Also, they had significantly elevated serum lipoprotein (a) levels than controls. Conclusion: Based on our study findings, we can conclude that because of the potential role of lipoprotein (a) in the development of cardiovascular disease, it is imperative to include an estimation of lipoprotein (a) levels in all CKD patients, especially in later stages to give a targeted therapy for dyslipidemia among CKD patients